Krystal Biotech Stock Performance
| KRYS Stock | USD 196.91 0.39 0.20% |
Krystal Biotech has a performance score of 3 on a scale of 0 to 100. The company secures a Beta (Market Risk) of 1.54, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Krystal Biotech will likely underperform. Krystal Biotech right now secures a risk of 2.39%. Please verify Krystal Biotech treynor ratio, expected short fall, as well as the relationship between the Expected Short fall and day median price , to decide if Krystal Biotech will be following its current price movements.
Risk-Adjusted Performance
3 of 100
Weak | Strong |
Weak
Compared to the overall equity markets, risk-adjusted returns on investments in Krystal Biotech are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively weak basic indicators, Krystal Biotech may actually be approaching a critical reversion point that can send shares even higher in December 2024. ...more
Actual Historical Performance (%)
One Day Return 0.2 | Five Day Return 6.98 | Year To Date Return 57.58 | Ten Year Return 1.8 K | All Time Return 1.8 K |
1 | Disposition of 5109 shares by Suma Krishnan of Krystal Biotech at 170.3241 subject to Rule 16b-3 | 09/06/2024 |
2 | RZLT Stock Up as FDA Lifts Clinical Holds on Rare Disease Study | 09/10/2024 |
3 | Bristol Myers Stock Up on FDA Nod for Schizophrenia Treatment | 09/27/2024 |
4 | Krystal Biotech, Inc. to Report Q3 Results Wall Street Expects Earnings Growth | 10/28/2024 |
5 | Are Options Traders Betting on a Big Move in Krystal Biotech Stock | 11/01/2024 |
6 | Krystal Biotech Announces Third Quarter 2024Financial Results and Provides Business Updates | 11/04/2024 |
7 | Krystal Biotech Third Quarter 2024 Earnings EPS Beats Expectations | 11/05/2024 |
8 | Krystal Biotech to Present at Guggenheim Securities Healthcare Innovation Conference | 11/06/2024 |
9 | Krystal Biotech, Inc. Just Released Its Third-Quarter Earnings Heres What Analysts Think | 11/07/2024 |
10 | High Growth Tech Stocks Featuring Three Prominent US Companies | 11/12/2024 |
11 | Avoro Capital Advisors LLC Increases Stake in Avidity Biosciences Inc | 11/14/2024 |
12 | First Turn Management LLC Sells 41,280 Shares of Krystal Biotech, Inc. - MarketBeat | 11/19/2024 |
| Begin Period Cash Flow | 161.9 M |
Krystal |
Krystal Biotech Relative Risk vs. Return Landscape
If you would invest 18,678 in Krystal Biotech on August 31, 2024 and sell it today you would earn a total of 1,013 from holding Krystal Biotech or generate 5.42% return on investment over 90 days. Krystal Biotech is currently generating 0.1116% in daily expected returns and assumes 2.3886% risk (volatility on return distribution) over the 90 days horizon. In different words, 21% of stocks are less volatile than Krystal, and 98% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Krystal Biotech Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Krystal Biotech's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Krystal Biotech, and traders can use it to determine the average amount a Krystal Biotech's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0467
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | KRYS | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 2.39 actual daily | 21 79% of assets are more volatile |
Expected Return
| 0.11 actual daily | 2 98% of assets have higher returns |
Risk-Adjusted Return
| 0.05 actual daily | 3 97% of assets perform better |
Based on monthly moving average Krystal Biotech is performing at about 3% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Krystal Biotech by adding it to a well-diversified portfolio.
Krystal Biotech Fundamentals Growth
Krystal Stock prices reflect investors' perceptions of the future prospects and financial health of Krystal Biotech, and Krystal Biotech fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Krystal Stock performance.
| Return On Equity | 0.0638 | ||||
| Return On Asset | 0.0458 | ||||
| Profit Margin | 0.22 % | ||||
| Operating Margin | 0.42 % | ||||
| Current Valuation | 5.08 B | ||||
| Shares Outstanding | 28.76 M | ||||
| Price To Earning | (6.36) X | ||||
| Price To Book | 6.39 X | ||||
| Price To Sales | 23.45 X | ||||
| Revenue | 50.7 M | ||||
| EBITDA | 17.9 M | ||||
| Net Income | 10.93 M | ||||
| Cash And Equivalents | 425.56 M | ||||
| Cash Per Share | 16.58 X | ||||
| Total Debt | 8.09 M | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 12.45 X | ||||
| Book Value Per Share | 30.80 X | ||||
| Cash Flow From Operations | (88.8 M) | ||||
| Earnings Per Share | 1.77 X | ||||
| Market Capitalization | 5.66 B | ||||
| Total Asset | 818.36 M | ||||
| Retained Earnings | (269.83 M) | ||||
| Working Capital | 554.82 M | ||||
| Current Asset | 2.05 M | ||||
| Current Liabilities | 40.74 K | ||||
About Krystal Biotech Performance
Assessing Krystal Biotech's fundamental ratios provides investors with valuable insights into Krystal Biotech's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Krystal Biotech is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 741.62 | 659.22 | |
| Return On Tangible Assets | 0.01 | 0.01 | |
| Return On Capital Employed | (0.14) | (0.15) | |
| Return On Assets | 0.01 | 0.01 | |
| Return On Equity | 0.01 | 0.01 |
Things to note about Krystal Biotech performance evaluation
Checking the ongoing alerts about Krystal Biotech for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Krystal Biotech help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Krystal Biotech currently holds about 425.56 M in cash with (88.8 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 16.58. | |
| Over 88.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: First Turn Management LLC Sells 41,280 Shares of Krystal Biotech, Inc. - MarketBeat |
- Analyzing Krystal Biotech's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Krystal Biotech's stock is overvalued or undervalued compared to its peers.
- Examining Krystal Biotech's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Krystal Biotech's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Krystal Biotech's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Krystal Biotech's stock. These opinions can provide insight into Krystal Biotech's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Krystal Stock Analysis
When running Krystal Biotech's price analysis, check to measure Krystal Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Krystal Biotech is operating at the current time. Most of Krystal Biotech's value examination focuses on studying past and present price action to predict the probability of Krystal Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Krystal Biotech's price. Additionally, you may evaluate how the addition of Krystal Biotech to your portfolios can decrease your overall portfolio volatility.